Search

Sanofi SA

Închisă

SectorSănătate

81.04 0.07

Rezumat

Modificarea prețului

24h

Curent

Minim

80.98

Maxim

81.19

Indicatori cheie

By Trading Economics

Venit

3.9B

5.8B

Vânzări

11B

21B

P/E

Medie Sector

15.922

34.393

EPS

1.59

Randament dividend

4.88

Marjă de profit

27.234

Angajați

82,878

EBITDA

2.2B

2.8B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+33.26% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.88%

2.54%

Următoarele câștiguri

24 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-4.1B

100B

Deschiderea anterioară

80.97

Închiderea anterioară

81.04

Sentimentul știrilor

By Acuity

34%

66%

90 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Sanofi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2025, 10:06 UTC

Principalele dinamici ale pieței

U.K. Bank Shares Rise After Car-Loan Ruling Softens Industry Blow -- Update

31 iul. 2025, 06:00 UTC

Câștiguri

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

30 iul. 2025, 10:20 UTC

Câștiguri

Santander Reports Higher Profit, but Regional Picture is Mixed -- Update

30 iul. 2025, 05:31 UTC

Câștiguri

Santander Sticks to Guidance, Launches $2 Billion Buyback After Profit Rises

6 aug. 2025, 05:02 UTC

Achiziții, Fuziuni, Preluări

Sanofi Completes the Acquisition of Vigil Neuroscience

6 aug. 2025, 05:00 UTC

Achiziții, Fuziuni, Preluări

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1 aug. 2025, 13:16 UTC

Câștiguri

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 aug. 2025, 12:40 UTC

Câștiguri

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31 iul. 2025, 08:15 UTC

Market Talk
Câștiguri

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31 iul. 2025, 05:56 UTC

Market Talk
Câștiguri

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi Intends to Complete EUR5B Buyback in 2025, With 80% Repurchased to Date

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi: 2025 Business EPS Guidance Now Includes Expenses From Acquisitions

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi 2Q Business Operating Profit EUR2.46B

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi 2Q Adj EPS EUR1.59

31 iul. 2025, 05:30 UTC

Câștiguri

Analysts Saw Sanofi 2Q Business Operating Profit at EUR2.57B

31 iul. 2025, 05:30 UTC

Câștiguri

Analysts Saw Sanofi 2Q Net Sales at EUR9.77B

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi 2Q Net Pft EUR3.94B

31 iul. 2025, 05:30 UTC

Câștiguri

Analysts Saw Sanofi 2Q Business EPS at EUR1.64

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi Now Expects 2025 Sales Growth at Constant Currency at High Single-Digit Percentage

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi Had Seen 2025 Sales Growth at Constant Currency at Mid-To-High Single-digit

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi 2Q Sales EUR9.99B

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi Backs 2025 EPS Adj View

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi Narrows 2025 Sales View

31 iul. 2025, 05:30 UTC

Câștiguri

Sanofi Confirms Expectations of Business EPS Rebound in 2025 Before Buybacks

30 iul. 2025, 07:48 UTC

Market Talk
Câștiguri

Santander Results Get Lukewarm Reaction -- Market Talk

30 iul. 2025, 06:41 UTC

Market Talk
Câștiguri

Santander's Strategic Investments in Focus -- Market Talk

30 iul. 2025, 04:52 UTC

Câștiguri

Santander End-2Q CET1 Ratio 13%

Comparație

Modificare preț

Sanofi SA Așteptări

Obiectiv de preț

By TipRanks

33.26% sus

Prognoză pe 12 luni

Medie 107.845 EUR  33.26%

Maxim 124 EUR

Minim 90 EUR

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSanofi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

14 ratings

10

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

91.3 / 96.1Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

90 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.